Splicing and Multifactorial Analysis of Intronic BRCA1 and BRCA2 Sequence Variants Identifies Clinically Significant Splicing Aberrations up to 12 Nucleotides from the Intron/Exon Boundary
Phillip J Whiley, Lucia Guidugli, Logan C Walker, Sue Healey, Bryony A Thompson, Sunil R Lakhani, Leonard M Da Silva, Sean V Tavtigian, David E Goldgar, Melissa A Brown, Fergus J Couch, Amanda B Spurdle
Human Mutation | WILEY-BLACKWELL | Published : 2011
Awarded by National Health and Medical Research Council (NHMRC)
Awarded by NIH
Contract grant sponsor: The National Health and Medical Research Council (NHMRC); Contract grant number: ID442970; Contract grant sponsor: NIH; Contract grant number: CA116167; Contract grant sponsor: NIH Breast Cancer Specialized Program of research Excellence (SPORE); Contract grant number: P50 CA116201; Contract grant sponsors: National Breast Cancer Foundation (to kConFab); The NHMRC (to kConFab); The Queensland Cancer Fund (to kConFab); The Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia (to kConFab); The Cancer Foundation of Western Australia (to kConFab); NHMRC; Contract grant numbers: 145684; 288704 (to the kConFab Clinical Follow-Up Study).We gratefully acknowledge the participation of the families concerned. We thank Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow-Up Study for their contributions to this resource, and the many families who contribute to kConFab. We thank Maxime Vallee for helpful discussions. We also acknowledge Linda Wadum, Kiley Johnson, Jennifer Mentlick, and Mary Karaus for their efforts to recruit the US-based families to these studies. We thank Myriad Genetic Laboratories for information used to derive family history scores and investigate co-occurrence of variants with pathogenic mutations. P.W. was awarded a scholarship by the QIMR Higher Degrees Committee. A.B.S. is an NHMRC Senior Research Fellow, L.Da.S. was supported by a fellowship from the Ludwig Institute for Cancer Research. L.W. is a John Gavin postdoctoral fellow. L.G. is supported by a fellowship from the Komen Foundation for the Cure.